表紙:過敏性腸症候群(IBS)治療市場- 成長、将来展望、競合分析、2023年~2031年
市場調査レポート
商品コード
1402958

過敏性腸症候群(IBS)治療市場- 成長、将来展望、競合分析、2023年~2031年

Irritable Bowel Syndrome Treatment Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031

出版日: | 発行: Acute Market Reports | ページ情報: 英文 117 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.16円
過敏性腸症候群(IBS)治療市場- 成長、将来展望、競合分析、2023年~2031年
出版日: 2023年12月15日
発行: Acute Market Reports
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

過敏性腸症候群(IBS)治療市場は、2023年から2031年の予測期間中にCAGR 10.5%で成長する見込みです。IBS治療は、腹痛、腹部膨満感、腸習慣の変化を特徴とする胃腸障害であるIBSに苦しむ人々を救済する上で重要な役割を果たしています。2022年現在、IBSに対する認識の高まりと効果的な治療法に対する需要に牽引され、市場は安定した成長を示しています。IBS市場は、IBSに対する認識の高まり、治療選択肢の進歩、有病率の上昇に牽引され、継続的な成長が見込まれます。治療の限界は依然として足かせとなっています。主要企業は技術革新と患者重視の戦略を通じて競合優位性を維持し、2022年から2031年にかけて売上が増加すると予測されます。2023年から2031年までの期間を展望すると、市場は新たな治療選択肢と地理的拡大により進化を続けると予想されます。

IBSに対する認識の高まり

2022年、過敏性腸症候群(IBS)治療市場は、一般人口の間でIBSに対する認識が高まっていることから大きな成長を遂げました。症状を認識し、診断と治療を求める人が増えています。このような意識の高まりがIBS治療に対する需要の高まりにつながり、意識が重要な推進力となっています。この動向は2023年から2031年まで主要な推進力として継続すると予想されます。

IBS治療の進歩

IBS治療法の進歩も市場を牽引しました。IBSの症状を緩和するために、処方薬と市販薬の両方で新しい薬や治療法が導入されています。これらの治療法は、個人の生活の質を向上させ、さまざまな選択肢を提供します。治療法の進歩は続いており、予測期間中に高いCAGRで市場の成長を牽引すると予想されます。

IBSの有病率の上昇

もう一つの重要な促進要因は、IBSの有病率の上昇です。IBSは世界人口のかなりの部分が罹患しており、一般的な胃腸疾患となっています。IBSは慢性疾患であるため、患者は継続的な治療を必要とし、市場の成長に寄与しています。IBSの有病率は上昇を続けており、2023年から2031年にかけて治療オプションの需要が高まることが予想されます。

過敏性腸症候群(IBS)治療市場の抑制要因

過敏性腸症候群(IBS)治療市場はその成長にもかかわらず、治療の制限に関連する抑制要因に直面しています。2022年、IBSの治療は根本的な原因に対処するのではなく、症状の管理に重点が置かれていました。決定的な治療法がないことが抑制要因となっています。この治療の限界は2023年から2031年まで続くと予想され、より効果的な治療法を開発するための継続的な研究努力が必要となります。

タイプ別市場セグメンテーション:IBS-D治療薬が市場を独占

過敏性腸症候群(IBS)治療市場は、タイプ別にIBS-C(便秘優位型)とIBS-D(下痢優位型)に区分できます。2022年には、このIBSサブタイプの有病率が高いことから、IBS-D治療薬の売上が最も高くなります。しかし、2023年から2031年までの予測期間では、IBS-C治療薬が最も高いCAGRを示すと予想され、このサブタイプに対するより効果的な治療オプションの必要性が示されています。

製品別市場セグメンテーション:リンゼス/Constellaが市場を独占

もう一つの重要なセグメンテーション要因は、IBS治療薬の製品カテゴリーであり、これはXifaxan、Linzess/Constella、Viberzi、Amitiza、その他に分けられます。2022年には、症状管理における有効性で知られるリンゼス/コンステラからの売上が最も高かったです。しかし、2023年から2031年までの予測期間中、IBS症状への対処において的を絞ったアプローチを提供し、患者の間で人気を集めているキシファキサンが最も高いCAGRを示すと予想されます。

北米が世界のリーダーであり続ける

地域別では、過敏性腸症候群(IBS)治療市場は多様な動向を示しています。北米は2022年に最も高い売上比率を記録したが、これは確立されたヘルスケアシステムとIBSに対する高い認知度が原動力となっています。しかし、アジア太平洋地域は、新興市場においてIBS治療に対する認識とアクセスが高まることから、2023年から2031年にかけて最も高いCAGRを記録すると予想されます。

市場競争は予測期間中に激化へ

過敏性腸症候群(IBS)治療市場は、Allergan、武田薬品工業、AbbVie.、武田薬品工業、Pfizer, Inc.、Abbott Laboratories、Novartis AG、AstraZeneca PLC、Ironwood Pharmaceuticals Inc.、Bausch Health Companies Inc.、GlaxoSmithKline, Plc.、Lexicon Pharmaceuticals, Inc.、Sucampo Pharmaceuticals, Inc.などの主要企業間の競争によって特徴付けられています。これらの企業は、IBS治療の改善と市場プレゼンス拡大のため、一貫して研究開発に投資してきました。2022年には大幅な収益を記録しており、2023年から2031年にかけても戦略的投資により高い収益が期待できます。主な戦略には、新たな治療選択肢の導入、患者サポートの改善、IBS治療を必要とするより多くの人々に届けるための流通網の拡大などがあります。

本レポートでお答えする主な質問

過敏性腸症候群(IBS)治療市場の成長に影響を与える主要なミクロおよびマクロ環境要因は何か?

現在および予測期間中の製品セグメントと地域に関する主な投資ポケットは何か?

2031年までの推定推計・市場予測

予測期間中に最も速いCAGRを占めるセグメントは?

市場シェアの大きいセグメントとその理由は?

中低所得国は過敏性腸症候群(IBS)治療市場に投資しているか?

過敏性腸症候群(IBS)治療市場で最大の地域市場はどこか?

アジア太平洋、ラテンアメリカ、中東・アフリカなどの新興市場における市場動向と力学は?

過敏性腸症候群(IBS)治療市場の成長を促進する主要動向は?

世界の過敏性腸症候群(IBS)治療市場で存在感を高めるための主要な競合企業とその主要戦略とは?

目次

第1章 序文

  • レポート内容
    • 報告書の目的
    • 対象者
    • 主な提供商品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ-二次調査
    • フェーズⅡ-一次調査
    • フェーズⅢ-有識者レビュー
    • 前提条件
    • 採用したアプローチ

第2章 エグゼクティブサマリー

第3章過敏性腸症候群(IBS)治療市場:競合分析

  • 主要ベンダーの市場での位置付け
  • ベンダーが採用する戦略
  • 主要な産業戦略
  • ティア分析:2022 vs 2031年

第4章過敏性腸症候群(IBS)治療市場:マクロ分析と市場力学

  • イントロダクション
  • 世界の過敏性腸症候群(IBS)治療市場金額 2021-2031年
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
    • サプライヤーパワー
    • バイヤーパワー
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競争企業間の敵対関係
  • PESTEL分析
    • 政治的情勢
    • 経済情勢
    • テクノロジーの情勢
    • 法的情勢
    • 社会的情勢

第5章過敏性腸症候群(IBS)治療市場:タイプ別 2021-2031年

  • 市場概要
  • 成長・収益分析:2022 vs 2031年
  • 市場セグメンテーション
    • IBS-C
      • リンゼス/コンステラ
      • アミティザ
      • その他
    • IBS-D
      • シファクサン
      • ヴィベルジ
      • その他

第6章過敏性腸症候群(IBS)治療市場:製品別 2021-2031年

  • 市場概要
  • 成長・収益分析:2022 vs 2031年
  • 市場セグメンテーション
    • シファクサン
    • リンゼス/コンステラ
    • ヴィベルジ
    • アミティザ
    • その他

第7章 北米の過敏性腸症候群(IBS)治療市場 2021-2031年

  • 市場概要
  • 過敏性腸症候群(IBS)治療市場:タイプ別 2021-2031年
  • 過敏性腸症候群(IBS)治療市場:製品別 2021-2031年
  • 過敏性腸症候群(IBS)治療市場:地域別 2021-2031年
    • 北米
      • 米国
      • カナダ
      • その他北米地域

第8章 英国と欧州連合の過敏性腸症候群(IBS)治療市場 2021-2031年

  • 市場概要
  • 過敏性腸症候群(IBS)治療市場:タイプ別 2021-2031年
  • 過敏性腸症候群(IBS)治療市場:製品別 2021-2031年
  • 過敏性腸症候群(IBS)治療市場:地域別 2021-2031年
    • 英国と欧州連合
      • 英国
      • ドイツ
      • スペイン
      • イタリア
      • フランス
      • その他欧州地域

第9章 アジア太平洋の過敏性腸症候群(IBS)治療市場 2021-2031年

  • 市場概要
  • 過敏性腸症候群(IBS)治療市場:タイプ別 2021-2031年
  • 過敏性腸症候群(IBS)治療市場:製品別 2021-2031年
  • 過敏性腸症候群(IBS)治療市場:地域別 2021-2031年
    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域

第10章 ラテンアメリカの過敏性腸症候群(IBS)治療市場 2021-2031年

  • 市場概要
  • 過敏性腸症候群(IBS)治療市場:タイプ別 2021-2031年
  • 過敏性腸症候群(IBS)治療市場:製品別 2021-2031年
  • 過敏性腸症候群(IBS)治療市場:地域別 2021-2031年
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • その他ラテンアメリカ地域

第11章 中東・アフリカの過敏性腸症候群(IBS)治療市場 2021-2031年

  • 市場概要
  • 過敏性腸症候群(IBS)治療市場:タイプ別 2021-2031年
  • 過敏性腸症候群(IBS)治療市場:製品別 2021-2031年
  • 過敏性腸症候群(IBS)治療市場:地域別 2021-2031年
    • 中東・アフリカ
      • GCC
      • アフリカ
      • その他中東・アフリカ地域

第12章 企業プロファイル

  • Allergan
  • Takeda Pharmaceutical Company
  • AbbVie.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Abbott Laboratories
  • Novartis AG
  • AstraZeneca PLC
  • Ironwood Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • GlaxoSmithKline Plc.
  • Lexicon Pharmaceuticals Inc.
  • Sucampo Pharmaceuticals Inc.
  • その他の主要企業
図表

List of Tables

  • TABLE 1 Global Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 2 Global Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 3 Global Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 4 Global Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 5 North America Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 6 North America Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 7 North America Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 8 North America Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 9 U.S. Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 10 U.S. Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 11 U.S. Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 12 U.S. Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 13 Canada Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 14 Canada Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 15 Canada Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 16 Canada Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 17 Rest of North America Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 18 Rest of North America Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 19 Rest of North America Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 20 Rest of North America Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 21 UK and European Union Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 22 UK and European Union Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 23 UK and European Union Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 24 UK and European Union Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 25 UK Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 26 UK Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 27 UK Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 28 UK Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 29 Germany Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 30 Germany Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 31 Germany Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 32 Germany Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 33 Spain Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 34 Spain Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 35 Spain Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 36 Spain Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 37 Italy Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 38 Italy Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 39 Italy Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 40 Italy Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 41 France Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 42 France Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 43 France Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 44 France Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 45 Rest of Europe Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 46 Rest of Europe Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 47 Rest of Europe Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 48 Rest of Europe Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 49 Asia Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 50 Asia Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 51 Asia Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 52 Asia Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 53 China Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 54 China Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 55 China Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 56 China Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 57 Japan Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 58 Japan Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 59 Japan Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 60 Japan Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 61 India Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 62 India Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 63 India Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 64 India Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 65 Australia Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 66 Australia Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 67 Australia Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 68 Australia Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 69 South Korea Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 70 South Korea Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 71 South Korea Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 72 South Korea Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 73 Latin America Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 74 Latin America Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 75 Latin America Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 76 Latin America Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 77 Brazil Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 78 Brazil Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 79 Brazil Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 80 Brazil Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 81 Mexico Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 82 Mexico Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 83 Mexico Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 84 Mexico Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 85 Rest of Latin America Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 86 Rest of Latin America Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 87 Rest of Latin America Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 88 Rest of Latin America Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 89 Middle East and Africa Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 90 Middle East and Africa Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 91 Middle East and Africa Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 92 Middle East and Africa Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 93 GCC Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 94 GCC Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 95 GCC Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 96 GCC Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 97 Africa Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 98 Africa Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 99 Africa Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 100 Africa Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

  • TABLE 101 Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Market By Type, 2021-2031, USD (Million)
  • TABLE 102 Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Market By IBS-C, 2021-2031, USD (Million)

TABLE 103 Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)

TABLE 104 Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Irritable Bowel Syndrome Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Irritable Bowel Syndrome Treatment Market: Quality Assurance
  • FIG. 5 Global Irritable Bowel Syndrome Treatment Market, By Type, 2022
  • FIG. 6 Global Irritable Bowel Syndrome Treatment Market, By Product, 2022
  • FIG. 7 Global Irritable Bowel Syndrome Treatment Market, By Geography, 2022
  • FIG. 8 Market Geographical Opportunity Matrix - Global Irritable Bowel Syndrome Treatment Market, 2022

FIG. 9Market Positioning of Key Irritable Bowel Syndrome Treatment Market Players, 2022

FIG. 10Global Irritable Bowel Syndrome Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 11 Global Irritable Bowel Syndrome Treatment Market, By Type, 2022 Vs 2031, %
  • FIG. 12 Global Irritable Bowel Syndrome Treatment Market, By Product, 2022 Vs 2031, %
  • FIG. 13 U.S. Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 14 Canada Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 15 Rest of North America Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 16 UK Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 17 Germany Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 18 Spain Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 19 Italy Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 20 France Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 21 Rest of Europe Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 22 China Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 23 Japan Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 24 India Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 25 Australia Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 26 South Korea Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 27 Rest of Asia Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 28 Brazil Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 29 Mexico Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 30 Rest of Latin America Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 31 GCC Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 32 Africa Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
  • FIG. 33 Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Market (US$ Million), 2021 - 2031
目次
Product Code: 140029-12-23

The irritable bowel syndrome (IBS) treatment market is expected to grow at a CAGR of 10.5% during the forecast period of 2023 to 2031. IBS treatment plays a vital role in providing relief to individuals suffering from IBS, a gastrointestinal disorder characterized by abdominal pain, bloating, and changes in bowel habits. As of 2022, the market exhibited steady growth, driven by increased awareness of IBS and the demand for effective treatments. The IBS market is poised for continued growth, driven by growing awareness of IBS, advancements in treatment options, and the rising prevalence of the condition. Treatment limitations remain a restraint. Key players are expected to maintain their competitive edge through innovation and patient-focused strategies, with revenues projected to rise from 2022 to 2031. Looking ahead to the period from 2023 to 2031, the market is expected to continue evolving with new treatment options and geographic expansion.

Growing Awareness of IBS

In 2022, the Irritable Bowel Syndrome Treatment Market witnessed significant growth due to the increasing awareness of IBS among the general population. More individuals are recognizing the symptoms and seeking diagnosis and treatment. This growing awareness led to higher demand for IBS treatments, making awareness a crucial driver. This trend is expected to continue as a key driver from 2023 to 2031.

Advancements in IBS Treatment

The market was also driven by advancements in IBS treatment options. New medications and therapies, both prescription and over-the-counter, have been introduced to provide relief from IBS symptoms. These treatments offer a range of options for individuals, improving their quality of life. As advancements in treatment continue, they are expected to drive market growth with a high CAGR during the forecast period.

Rising Prevalence of IBS

Another significant driver was the rising prevalence of IBS. The condition affects a substantial portion of the global population, making it a common gastrointestinal disorder. With IBS being a chronic condition, individuals require ongoing treatment, contributing to the market's growth. As the prevalence of IBS continues to rise, it is expected to drive demand for treatment options from 2023 to 2031.

Restraint in the Irritable Bowel Syndrome Treatment Market

Despite its growth, the Irritable Bowel Syndrome Treatment Market faces a restraint related to treatment limitations. In 2022, treatments for IBS focused on symptom management, rather than addressing the root cause of the condition. The absence of a definitive cure acted as a restraint. It is expected that this treatment limitation will continue to be a challenge from 2023 to 2031, necessitating ongoing research efforts to develop more effective treatments.

Market Segmentation by Type: IBS-D treatments Dominate the Market

The Irritable Bowel Syndrome Treatment Market can be segmented by type into IBS-C (Constipation-predominant) and IBS-D (Diarrhea-predominant). In 2022, the highest revenue was attributed to IBS-D treatments, given the high prevalence of this IBS subtype. However, during the forecast period from 2023 to 2031, IBS-C treatments are expected to exhibit the highest CAGR, indicating the need for more effective treatment options for this subtype.

Market Segmentation by Product: Linzess/Constella Dominate the Market

Another crucial segmentation factor is the product category of IBS treatments, which can be divided into Xifaxan, Linzess/Constella, Viberzi, Amitiza, and others. In 2022, the highest revenue came from Linzess/Constella, which are known for their effectiveness in symptom management. However, during the forecast period from 2023 to 2031, Xifaxan is expected to exhibit the highest CAGR, as it offers a targeted approach in addressing IBS symptoms and gaining popularity among patients.

North America Remains the Global Leader

Geographically, the Irritable Bowel Syndrome Treatment Market exhibits diverse trends. North America recorded the highest revenue percentage in 2022, driven by a well-established healthcare system and high awareness of IBS. However, the Asia-Pacific region is expected to have the highest CAGR from 2023 to 2031, as awareness and access to IBS treatments grow in emerging markets.

Market Competition to Intensify during the Forecast Period

The Irritable Bowel Syndrome Treatment Market is characterized by competition among key players, such as Allergan, Takeda Pharmaceutical Company, AbbVie., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Abbott Laboratories, Novartis AG, AstraZeneca PLC, Ironwood Pharmaceuticals Inc., Bausch Health Companies Inc., GlaxoSmithKline, Plc., Lexicon Pharmaceuticals, Inc. and Sucampo Pharmaceuticals, Inc. These companies have consistently invested in research and development to improve IBS treatments and expand their market presence. In 2022, they recorded substantial revenues, and it is expected that their strategic investments will continue to yield high returns from 2023 to 2031. Key strategies include introducing new treatment options, improving patient support, and expanding distribution networks to reach more individuals in need of IBS treatment.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofIrritable Bowel Syndrome Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Irritable Bowel Syndrome Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

    • IBS-C
  • Linzess/Constella
  • Amitiza
  • Others
    • IBS-D
  • Xifaxan
  • Viberzi
  • Others

Product

    • Xifaxan
    • Linzess/Constella
    • Viberzi
    • Amitiza
    • Others

Region Segment (2021-2031; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Irritable Bowel Syndrome Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2031.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Irritable Bowel Syndrome Treatment market?

Which is the largest regional market for Irritable Bowel Syndrome Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Irritable Bowel Syndrome Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Irritable Bowel Syndrome Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Irritable Bowel Syndrome Treatment Market
  • 2.2. Global Irritable Bowel Syndrome Treatment Market, By Type, 2022 (US$ Million)
  • 2.3. Global Irritable Bowel Syndrome Treatment Market, By Product, 2022 (US$ Million)
  • 2.4. Global Irritable Bowel Syndrome Treatment Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022

3. Irritable Bowel Syndrome Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Irritable Bowel Syndrome Treatment Market Vendors
  • 3.2. Strategies Adopted by Irritable Bowel Syndrome Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Irritable Bowel Syndrome Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Irritable Bowel Syndrome Treatment Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. IBS-C
      • 5.3.1.1. Linzess/Constella
      • 5.3.1.2. Amitiza
      • 5.3.1.3. Others
    • 5.3.2. IBS-D
      • 5.3.2.1. Xifaxan
      • 5.3.2.2. Viberzi
      • 5.3.2.3. Others

6. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Xifaxan
    • 6.3.2. Linzess/Constella
    • 6.3.3. Viberzi
    • 6.3.4. Amitiza
    • 6.3.5. Others

7. North America Irritable Bowel Syndrome Treatment Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
  • 7.3. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
  • 7.4.Irritable Bowel Syndrome Treatment Market: By Region, 2021-2031, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 7.4.1.1.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 7.4.1.2.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 7.4.1.3.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)

8. UK and European Union Irritable Bowel Syndrome Treatment Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
  • 8.3. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
  • 8.4.Irritable Bowel Syndrome Treatment Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.1.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.2.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.3.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.4.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.5.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 8.4.1.6.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)

9. Asia Pacific Irritable Bowel Syndrome Treatment Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
  • 9.3. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
  • 9.4.Irritable Bowel Syndrome Treatment Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.1.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.2.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.3.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.4.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.5.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 9.4.1.6.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)

10. Latin America Irritable Bowel Syndrome Treatment Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
  • 10.3. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
  • 10.4.Irritable Bowel Syndrome Treatment Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 10.4.1.1.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 10.4.1.2.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 10.4.1.3.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)

11. Middle East and Africa Irritable Bowel Syndrome Treatment Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
  • 11.3. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
  • 11.4.Irritable Bowel Syndrome Treatment Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 11.4.1.1.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 11.4.1.2.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Irritable Bowel Syndrome Treatment Market: By Type, 2021-2031, USD (Million)
        • 11.4.1.3.2. Irritable Bowel Syndrome Treatment Market: By Product, 2021-2031, USD (Million)

12. Company Profile

  • 12.1. Allergan
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Takeda Pharmaceutical Company
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. AbbVie.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Takeda Pharmaceutical Company Limited
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Pfizer, Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Abbott Laboratories
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Novartis AG
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. AstraZeneca PLC
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Ironwood Pharmaceuticals Inc.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Bausch Health Companies Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. GlaxoSmithKline, Plc.
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. Lexicon Pharmaceuticals, Inc.
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives
  • 12.13. Sucampo Pharmaceuticals, Inc.
    • 12.13.1. Company Overview
    • 12.13.2. Financial Performance
    • 12.13.3. Product Portfolio
    • 12.13.4. Strategic Initiatives
  • 12.14. Other Notable Players
    • 12.14.1. Company Overview
    • 12.14.2. Financial Performance
    • 12.14.3. Product Portfolio
    • 12.14.4. Strategic Initiatives